MEDICINOVA INC. - COM

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

05 Jan 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

06 Dec 2022 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

05 Dec 2022 18:00:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

15 Sep 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

14 Sep 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

13 Sep 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID

16 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

09 Aug 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

27 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

26 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

21 Jul 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

29 Jun 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

22 Jun 2022 19:00:04 By Nasdaq GlobeNewswire

MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

08 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference

21 Apr 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

20 Apr 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

12 Apr 2022 23:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

11 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

07 Apr 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

17 Mar 2022 06:30:00 By Nasdaq GlobeNewswire